DE69231495T2 - Neue cocain-derivate und protein- und polypeptid-cocain-derivate, konjugate und markierte verbindungen - Google Patents

Neue cocain-derivate und protein- und polypeptid-cocain-derivate, konjugate und markierte verbindungen

Info

Publication number
DE69231495T2
DE69231495T2 DE69231495T DE69231495T DE69231495T2 DE 69231495 T2 DE69231495 T2 DE 69231495T2 DE 69231495 T DE69231495 T DE 69231495T DE 69231495 T DE69231495 T DE 69231495T DE 69231495 T2 DE69231495 T2 DE 69231495T2
Authority
DE
Germany
Prior art keywords
derivatives
cocain
polypeptid
conjugates
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69231495T
Other languages
English (en)
Other versions
DE69231495D1 (de
Inventor
Francis Buechler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alere San Diego Inc
Original Assignee
Biosite Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosite Diagnostics Inc filed Critical Biosite Diagnostics Inc
Publication of DE69231495D1 publication Critical patent/DE69231495D1/de
Application granted granted Critical
Publication of DE69231495T2 publication Critical patent/DE69231495T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/946—CNS-stimulants, e.g. cocaine, amphetamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/12—Oxygen atoms acylated by aromatic or heteroaromatic carboxylic acids, e.g. cocaine
DE69231495T 1991-12-16 1992-12-16 Neue cocain-derivate und protein- und polypeptid-cocain-derivate, konjugate und markierte verbindungen Expired - Lifetime DE69231495T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/808,515 US5233042A (en) 1991-12-16 1991-12-16 Cocaine derivatives
PCT/US1992/010857 WO1993012111A1 (en) 1991-12-16 1992-12-16 Novel cocaine derivatives and protein and polypeptide cocaine derivative conjugates and labels

Publications (2)

Publication Number Publication Date
DE69231495D1 DE69231495D1 (de) 2000-11-09
DE69231495T2 true DE69231495T2 (de) 2001-05-31

Family

ID=25199002

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69231495T Expired - Lifetime DE69231495T2 (de) 1991-12-16 1992-12-16 Neue cocain-derivate und protein- und polypeptid-cocain-derivate, konjugate und markierte verbindungen

Country Status (7)

Country Link
US (1) US5233042A (de)
EP (1) EP0575581B1 (de)
AT (1) ATE196767T1 (de)
AU (1) AU3322093A (de)
CA (1) CA2106563C (de)
DE (1) DE69231495T2 (de)
WO (1) WO1993012111A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037455A (en) * 1992-11-09 2000-03-14 Biosite Diagnostics Incorporated Propoxyphene derivatives and protein and polypeptide propoxyphene derivative conjugates and labels
DE69332637T2 (de) * 1993-03-04 2003-10-23 Matsushita Electric Ind Co Ltd Kokainderivat,Proteinkonjugat,davon,einen monoklonalen Antikörper produzierende Hybridom-Zellinie, Verfahren zur Herstellung der Hybridom-Zellinie und des monoklonalen Antikörpers
US5283344A (en) * 1993-03-10 1994-02-01 Abbott Laboratories Coupling method using selective amination of maleimide
ES2210356T3 (es) * 1995-03-31 2004-07-01 Xenova Research Limited Conjugados de haptano-transportador para empleo en terapia contra el uso de drogas.
US5840307A (en) * 1995-03-31 1998-11-24 Immulogic Pharmacuetical Corp. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation
EP0967993A4 (de) 1995-12-14 2001-04-18 Scripps Research Inst Anti-kokaine vakzine
US5808074A (en) * 1996-02-02 1998-09-15 Georgetown University Benzoylecgonine conjugate diagnostic reagents
US5817770A (en) 1997-03-21 1998-10-06 Drug Abuse Sciences, Inc. Cocaethylene immunogens and antibodies
US7297554B2 (en) * 1998-11-18 2007-11-20 Microdiagnostics, Inc. Immunoassay system
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4045420A (en) * 1973-05-29 1977-08-30 Syva Company Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds polypeptide and derivatives thereof
US3888866A (en) * 1973-06-01 1975-06-10 Syva Co Nitrogen derivatives of benzoyl ecgonine
US3917582A (en) * 1973-06-13 1975-11-04 Syva Corp Isothiocyanate and thiourea derivatives of benzoyl ecgonine conjugated to polypeptides
US4102979A (en) * 1976-09-22 1978-07-25 Hoffmann-La Roche Inc. Radioimmunoassay for benzoylecgonine
US5155212A (en) * 1986-05-21 1992-10-13 Abbott Laboratories Phencyclidine and phencyclidine metabolites assay, tracers, immunogens, antibodies and reagent kit
US5238652A (en) * 1990-06-20 1993-08-24 Drug Screening Systems, Inc. Analytical test devices for competition assay for drugs of non-protein antigens using immunochromatographic techniques
DE69119312T2 (de) * 1990-07-18 1997-01-16 Abbott Lab Analyt-Austauschreagenz zur Verwendung in spezifischen Bindungstests, -vorrichtungen und -sätzen
US5143852A (en) * 1990-09-14 1992-09-01 Biosite Diagnostics, Inc. Antibodies to ligand analogues and their utility in ligand-receptor assays

Also Published As

Publication number Publication date
EP0575581B1 (de) 2000-10-04
CA2106563A1 (en) 1993-06-17
CA2106563C (en) 1997-11-25
ATE196767T1 (de) 2000-10-15
EP0575581A1 (de) 1993-12-29
DE69231495D1 (de) 2000-11-09
AU3322093A (en) 1993-07-19
WO1993012111A1 (en) 1993-06-24
US5233042A (en) 1993-08-03

Similar Documents

Publication Publication Date Title
DE69225757D1 (de) Lyophilische monoklonale antikörperpräparationen
DK261386A (da) Monoklonale antistoffer
DE69325096D1 (de) Morphinderivate sowie deren konjugate und labels mit proteinen und polypeptiden
NO171223C (no) Monoklonalt reseptormolekyl eller del derav som omfatter det antistoffbindende sete, for in vitro bruk, samt in vitro anvendelse derav
DE69231495D1 (de) Neue cocain-derivate und protein- und polypeptid-cocain-derivate, konjugate und markierte verbindungen
DK63187D0 (da) Krydsbeskyttende monoklonale antistofpraeparater
DE69317886D1 (de) Neue propoxyphenderivate sowie deren protein-und polypeptidlabels und-konjugate
ATE193534T1 (de) Benzodiazepin-derivate sowie deren konjugate mit proteinen und polypeptiden
DK101196A (da) Histaminderivat, histamin-immunogen-konjugat samt antistof fremstillet mod konjugatet
DE69115104D1 (de) Composition comprising at least two different antibodies or fragments thereof.
DE69611037T2 (de) Methadonderivate und protein- und polypeptid-methadonkonjugate und markierte verbindungen
EP0269677A4 (de) Testverfahren und antikörper für n-myc-proteine.
ATE137410T1 (de) Konjugate von &#39;&#39;pokeweed&#39;&#39; antiviralem protein und monoklonalen antikörpern
ES2163648T3 (es) Conjugados de quinidina y su uso en inmunoensayos.
DE69111429D1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
SE8705137D0 (sv) Diagnostic method for primary biliary cirrhosis and antibodies suitable to be used in certain versions of the method
IL80918A (en) Monoclonal antibodies cross-reactive and cross-protective against p.aeruginosa serotypes and pharmaceutical compositions and kits containing said antibodies
SE9002479D0 (sv) Antibody conjugates
KR860008779A (ko) 항체 형성 화합물의 제조방법

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 575581

Country of ref document: EP